ATXS
Price
$5.52
Change
+$0.12 (+2.22%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
304.74M
35 days until earnings call
CLDX
Price
$17.37
Change
+$0.52 (+3.09%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
1.15B
28 days until earnings call
Ad is loading...

ATXS vs CLDX

Header iconATXS vs CLDX Comparison
Open Charts ATXS vs CLDXBanner chart's image
Astria Therapeutics
Price$5.52
Change+$0.12 (+2.22%)
Volume$2.21K
Capitalization304.74M
Celldex Therapeutics
Price$17.37
Change+$0.52 (+3.09%)
Volume$30.36K
Capitalization1.15B
ATXS vs CLDX Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. CLDX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and CLDX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ATXS: $5.40 vs. CLDX: $16.85)
Brand notoriety: ATXS and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 154% vs. CLDX: 140%
Market capitalization -- ATXS: $304.74M vs. CLDX: $1.15B
ATXS [@Biotechnology] is valued at $304.74M. CLDX’s [@Biotechnology] market capitalization is $1.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, CLDX is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while CLDX’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • CLDX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ATXS and CLDX are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -13.60% price change this week, while CLDX (@Biotechnology) price change was -16.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

ATXS is expected to report earnings on May 08, 2025.

CLDX is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.15B) has a higher market cap than ATXS($305M). CLDX YTD gains are higher at: -33.320 vs. ATXS (-39.597). ATXS has higher annual earnings (EBITDA): -111.56M vs. CLDX (-191.9M). CLDX has more cash in the bank: 725M vs. ATXS (328M). CLDX has less debt than ATXS: CLDX (3.81M) vs ATXS (5.35M). CLDX has higher revenues than ATXS: CLDX (7.02M) vs ATXS (0).
ATXSCLDXATXS / CLDX
Capitalization305M1.15B26%
EBITDA-111.56M-191.9M58%
Gain YTD-39.597-33.320119%
P/E RatioN/AN/A-
Revenue07.02M-
Total Cash328M725M45%
Total Debt5.35M3.81M140%
FUNDAMENTALS RATINGS
ATXS vs CLDX: Fundamental Ratings
ATXS
CLDX
OUTLOOK RATING
1..100
8164
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
9289
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (57) in the Biotechnology industry is in the same range as ATXS (63). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

CLDX's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for ATXS (100). This means that CLDX’s stock grew somewhat faster than ATXS’s over the last 12 months.

CLDX's SMR Rating (96) in the Biotechnology industry is in the same range as ATXS (97). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

CLDX's Price Growth Rating (89) in the Biotechnology industry is in the same range as ATXS (92). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

CLDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATXS (100). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCLDX
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Bullish Trend 22 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAYBX36.100.06
+0.17%
Oakmark Equity and Income Advisor
HHDFX34.93N/A
N/A
Hamlin High Dividend Equity Instl
RYEUX111.23N/A
N/A
Rydex Europe 1.25x Strategy H
CREEX9.91N/A
N/A
Columbia Real Estate Equity Inst
JEEIX15.92N/A
N/A
JHancock Infrastructure I

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.12%
KYMR - ATXS
49%
Loosely correlated
-7.80%
DNLI - ATXS
48%
Loosely correlated
-9.60%
TRDA - ATXS
48%
Loosely correlated
-3.10%
ABOS - ATXS
47%
Loosely correlated
-2.27%
IMNM - ATXS
46%
Loosely correlated
-6.98%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with DNLI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-7.16%
DNLI - CLDX
47%
Loosely correlated
-9.60%
KYMR - CLDX
44%
Loosely correlated
-7.80%
BEAM - CLDX
43%
Loosely correlated
-9.70%
AXON - CLDX
43%
Loosely correlated
+2.90%
ATXS - CLDX
42%
Loosely correlated
+1.12%
More